Vaughan Nelson Investment Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Vaughan Nelson Investment Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-6,670	Closed	-$1.82M	–	209
2024 Q2	$1.82M	Buy	6,670 +660	+11%	+$192K	0.02%	161
2024 Q1	$2.08M	Buy	6,010 +1,470	+32%	+$483K	0.02%	162
2023 Q4	$1.47M	Buy	4,540 +255	+6%	+$79.9K	0.01%	175
2023 Q3	$1.54M	Sell	4,285 -830	-16%	-$320K	0.02%	186
2023 Q2	$1.94M	Buy	5,115 +1,400	+38%	+$570K	0.02%	176
2023 Q1	$1.78M	Hold	3,715	–	–	0.02%	170
2022 Q4	$1.56M	Buy	3,715 +2,485	+202%	+$1M	0.02%	174
2022 Q3	$513K	Buy	+1,230	New	+$613K	0.01%	177

Other funds holding BIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vaughan Nelson Investment Management's BIO Position: Q3 2024 in Review

Vaughan Nelson Investment Management sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2024, closing a stake of 6,670 shares — an estimated $1.82M sold.

Vaughan Nelson Investment Management first reported a position in BIO in Q3 2022 and held it in 8 quarters. The position peaked at $2.08M in Q1 2024. 438 funds tracked by Wall St. Rank hold BIO as of Q3 2024.

Vaughan Nelson Investment Management reported no remaining Bio-Rad Laboratories Class A position as of Q3 2024 after selling out during the quarter.
Vaughan Nelson Investment Management sold 6,670 Bio-Rad Laboratories Class A shares in Q3 2024, an estimated $1.82M.
Vaughan Nelson Investment Management first reported a position in Bio-Rad Laboratories Class A in Q3 2022 and held it in 8 quarters.
Vaughan Nelson Investment Management's Bio-Rad Laboratories Class A position peaked at $2.08M in Q1 2024.
438 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2024.

Based on Vaughan Nelson Investment Management's 13F filing for Q3 2024, filed 6 Nov 2024.